Qyuns Therapeutics Co., Ltd. (02509) Reports January 2026 Monthly Return and Share Repurchase Update

Bulletin Express02-05

Qyuns Therapeutics Co., Ltd. (02509) published its monthly return for January 2026, confirming the authorized share capital remains unchanged at 227,071,600 renminbi-denominated ordinary shares, each with a par value of RMB1.

The report shows that the total number of issued shares remained at 227,071,600, comprising 224,874,600 issued shares (excluding treasury shares) and 2,197,000 treasury shares at the end of January. Compared to the previous month, 685,000 shares were repurchased at prices ranging from HKD 19.0769 to HKD 23.1372 on multiple occasions throughout January 2026, thereby increasing the total treasury shares by the same amount.

The company states it has met the Hong Kong Stock Exchange’s public float requirement, which stands at a minimum threshold of 25% for its H shares. The submission was made in compliance with all applicable listing rules and regulatory requirements. No other share options, warrants, convertibles, or similar arrangements were reported for the period.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1135648336?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 10:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135648336","market":"hk","top_or_hot":-1,"title":"Qyuns Therapeutics Co., Ltd. (02509) Reports January 2026 Monthly Return and Share Repurchase Update","media":"Bulletin Express","content":"<p>Qyuns Therapeutics Co., Ltd. (02509) published its monthly return for January 2026, confirming the authorized share capital remains unchanged at 227,071,600 renminbi-denominated ordinary shares, each with a par value of RMB1.</p>\n<p>The report shows that the total number of issued shares remained at 227,071,600, comprising 224,874,600 issued shares (excluding treasury shares) and 2,197,000 treasury shares at the end of January. Compared to the previous month, 685,000 shares were repurchased at prices ranging from HKD 19.0769 to HKD 23.1372 on multiple occasions throughout January 2026, thereby increasing the total treasury shares by the same amount.</p>\n<p>The company states it has met the Hong Kong Stock Exchange’s public float requirement, which stands at a minimum threshold of 25% for its H shares. The submission was made in compliance with all applicable listing rules and regulatory requirements. No other share options, warrants, convertibles, or similar arrangements were reported for the period.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Qyuns Therapeutics Co., Ltd. (02509) Reports January 2026 Monthly Return and Share Repurchase Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQyuns Therapeutics Co., Ltd. (02509) Reports January 2026 Monthly Return and Share Repurchase Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-05 10:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Qyuns Therapeutics Co., Ltd. (02509) published its monthly return for January 2026, confirming the authorized share capital remains unchanged at 227,071,600 renminbi-denominated ordinary shares, each with a par value of RMB1.</p>\n<p>The report shows that the total number of issued shares remained at 227,071,600, comprising 224,874,600 issued shares (excluding treasury shares) and 2,197,000 treasury shares at the end of January. Compared to the previous month, 685,000 shares were repurchased at prices ranging from HKD 19.0769 to HKD 23.1372 on multiple occasions throughout January 2026, thereby increasing the total treasury shares by the same amount.</p>\n<p>The company states it has met the Hong Kong Stock Exchange’s public float requirement, which stands at a minimum threshold of 25% for its H shares. The submission was made in compliance with all applicable listing rules and regulatory requirements. No other share options, warrants, convertibles, or similar arrangements were reported for the period.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02509","symbol_name":"荃信生物-B","start_time":0,"source_url":"","article_id":"1135648336","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135648336","pubTimestamp":1770258278,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Qyuns Therapeutics Co., Ltd. (02509) published its monthly return for January 2026, confirming the authorized share capital remains unchanged at 227,071,600 renminbi-denominated ordinary shares, each...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02509":"荃信生物-B"},"translate_title":"Qyuns Therapeutics Co., Ltd.(02509)呈报2026年1月月报表及股份购回更新","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02509":1},"content_text":"Qyuns Therapeutics Co., Ltd. (02509) published its monthly return for January 2026, confirming the authorized share capital remains unchanged at 227,071,600 renminbi-denominated ordinary shares, each with a par value of RMB1.\nThe report shows that the total number of issued shares remained at 227,071,600, comprising 224,874,600 issued shares (excluding treasury shares) and 2,197,000 treasury shares at the end of January. Compared to the previous month, 685,000 shares were repurchased at prices ranging from HKD 19.0769 to HKD 23.1372 on multiple occasions throughout January 2026, thereby increasing the total treasury shares by the same amount.\nThe company states it has met the Hong Kong Stock Exchange’s public float requirement, which stands at a minimum threshold of 25% for its H shares. The submission was made in compliance with all applicable listing rules and regulatory requirements. No other share options, warrants, convertibles, or similar arrangements were reported for the period.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1135648336","isCrawlerRequest":true}